EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta‐analysis

Hao Chen iD, Masashi Ishihara, Hiroki Kazahari, Ryusuke Ochiai, Shigeru Tanzawa, Takeshi Honda, Yasuko Ichikawa, Nobuyuki Horita iD, Hisashi Nagai, Kiyotaka Watanabe, Nobuhiko Seki

Cancer Medicine · 2024

DOI: 10.1002/cam4.70166 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Medicine, 2024. Verfasst von Hao Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Teikyo University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Cachexia, Neoplasms, Olanzapine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer cachexia affects more than half of all cancer patients, reducing survival rates. Evidence‐based approaches are urgently needed to optimize treatment.

Methods

A systematic review and network meta‐analysis were conducted to assess the effectiveness and safety of different pharmacotherapies for cancer cachexia. Three databases (PubMed, Cochrane Library, and Web of Science) were searched for the period from January 1, 2000, to March 20, 2024. The netmeta package in R software was used to calculate the pooled effect, employing a random effects model.

Results

Seven placebo‐controlled randomized trials involving 1421 patients were analyzed. Pairwise analysis showed that body weight increases were 4.6 kg (95% confidence interval [CI] 0.83–8.37 kg) for olanzapine, 3.82 kg (95% CI 0.73–6.91 kg) for espindolol (20 mg), 2.36 kg (95% CI 1.84–2.89 kg) for anamorelin (100 mg), and 1.31 kg (95% CI 0.42–2.19 kg) for anamorelin (50 mg). In terms of safety profiles, olanzapine demonstrated the lowest odds ratio when compared to placebo, at 0.26 (95% CI 0.07–0.94), followed by anamorelin (50 mg) at 0.86 (95% CI 0.30–2.48), and anamorelin (100 mg) at 0.89 (95% CI 0.42–1.88). However, network meta‐analysis could not confirm the superiority of olanzapine over anamorelin in terms of efficacy and safety.

Conclusion

Both olanzapine and anamorelin are useful in improving body weight in patients with cancer cachexia. Personalization may be helpful for different patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaNeoplasmsOlanzapineHumansHydrazinesOligopeptidesRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

anamorelinbody weightcancer cachexianetwork meta‐analysisolanzapine

Substanzen

anamorelinHydrazinesOlanzapineOligopeptides

Autor:innen und Institutionen

  • Department of Oncology, Teikyo University School of Medicine, Tokyo, Japan.
  • Department of Pulmonology, Yokohama City University Hospital, Yokohama, Japan.
  • Department of Chemotherapy, Yokohama City University Hospital, Yokohama, Japan.
  • Graduate School of Human and Environmental Studies, Tokai University, Tokyo, Japan.

ORCID-Profile: Hao Chen, Nobuyuki Horita

Zitieren

APA

Chen, H., Ishihara, M., Kazahari, H., Ochiai, R., Tanzawa, S., Honda, T., Ichikawa, Y., Horita, N., Nagai, H., Watanabe, K., & Seki, N. (2024). Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta‐analysis. Cancer Medicine. https://doi.org/10.1002/cam4.70166

Vancouver

Chen H, Ishihara M, Kazahari H, Ochiai R, Tanzawa S, Honda T, et al. Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta‐analysis. Cancer Medicine. 2024. doi:10.1002/cam4.70166

BibTeX
@article{Chen2024,
  author = {Chen, Hao and Ishihara, Masashi and Kazahari, Hiroki and Ochiai, Ryusuke and Tanzawa, Shigeru and Honda, Takeshi and Ichikawa, Yasuko and Horita, Nobuyuki and Nagai, Hisashi and Watanabe, Kiyotaka and Seki, Nobuhiko},
  title = {Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta‐analysis},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70166}
}
Kostenlos starten →